In a multicenter , randomized , double-blind , placebo-controlled , parallel-group study , imeglimin ( @,@ mg b.i.d. ) or placebo was added to sitagliptin ( @ mg q.d. ) over @ weeks in @ patients with type @ diabetes ( mean age @ years ; BMI @ kg/m ( @ ) ) that was inadequately controlled with sitagliptin alone ( A@C @ % ) during a @-week run-in period .